ORMP

Congress Trades

Name	Value	Action	Amount Range	Price	Current Price
Brad KnottRepublican $33k SellJan 10, 2025 $15k-$50k -- --

News

prnewswire.comOramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexesprnewswire.comJun 17

seekingalpha.comOramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Directionseekingalpha.comMay 22

defenseworld.netReviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & Akanda (NASDAQ:AKAN)defenseworld.netApr 5

Trade ORMP

About Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.

CEO: Nadav Kidron
IPO Date: May 1, 2007

Market Data

Open: $3.86
High: $3.89
Low: $3.81
Volume: 148.9K
Avg Volume: 160.6K
52W High: $5.01
52W Low: $1.98

Valuation

Market Cap: $159M
Enterprise Value: $146M
Dividend Yield: 25.0%

Financials

Free Cash Flow: $-11M
Revenue: $2.0M
Net Income: $64M
Cash: $46M
Debt: $825k

Events

EarningsAug 13

EPS est. 0.15